

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

WEGO 威高

山東威高集團醫用高分子製品股份有限公司
Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

CHANGE OF BENCHMARK DATE UNDER THE ASSET TRANSFER AGREEMENT

Reference is made to the announcement (the “**Announcement**”) of Shandong Weigao Group Medical Polymer Company Limited (the “**Company**”) dated 15 June 2016 in relation to, among others, the Proposed Transaction. Capitalised terms used herein shall have the same meanings as defined in the Announcement unless the context requires otherwise.

As disclosed in the Announcement, the Issue Price for the issuance of the Consideration Shares by Winbase International under the Asset Transfer Agreement, which is RMB10.09 per Winbase Share, represents (i) a discount of approximately 16.9% to the average price of the Winbase Shares as quoted on the SSE for the consecutive 10 trading days immediately preceding the Benchmark Date; and (ii) a discount of approximately 10.3% to the average price of the Winbase Shares quoted on the SSE for the consecutive 20 trading days immediately preceding the Benchmark Date. “Benchmark Date” is defined as 14 June 2016 in the Announcement.

To comply with the relevant regulatory requirements of the PRC, on 13 December 2016, the board of directors of the Company resolved to change the Benchmark Date from 14 June 2016 to 14 December 2016. As trading in the Winbase Shares has suspended since early 2016, the change of the Benchmark Date does not affect the Issue Price, and the Issue Price remains to be RMB10.09 per Winbase Share.

* *For illustration purpose only*

The Company intends to enter into a supplemental agreement with the relevant parties to reflect the above-mentioned change in due course. The Company will make an announcement after the signing of such supplemental agreement by the relevant parties.

By Order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Zhang Hua Wei
Chairman

Weihai, Shandong, the PRC, 13 December 2016

As at the date of this announcement, the Board comprises:

Mr. Zhang Hua Wei (*Executive Director*)

Mr. Wang Yi (*Executive Director*)

Mr. Gong Jian Bo (*Executive Director*)

Mr. Xia Lie Bo (*Executive Director*)

Mrs. Zhou Shu Hua (*Non-executive Director*)

Mr. Lo Wai Hung (*Independent non-executive Director*)

Mr. Li Jia Miao (*Independent non-executive Director*)

Mrs. Fu Ming Zhong (*Independent non-executive Director*)

Mrs. Wang Jin Xia (*Independent non-executive Director*)